Key facts
- It has raised $200.0M across 1 recorded rounds; the latest was Later Stage VC ($62.0M) in Jan 2026.
- Notable investors include OrbiMed, Goldman Sachs Asset Management, Frazier Healthcare Partners, SR One Capital Management, Longitude Capital — 6 tracked in total.
- AirNexis Therapeutics has filed 1 Form D with the SEC, most recently Mar 2026 ($62.0M sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for AirNexis Therapeutics
Funding rounds
1 roundsAbout AirNexis Therapeutics
Developer of novel therapeutic drugs designed to provide treatment to COPD patients. The company develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions that exert synergistic effects through a dual mechanism of action that promotes bronchodilation and reduces the release of inflammatory factors, enabling healthcare professionals to provide quality care to patients.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Founded
- 2025
- Website
- airnexis.com/
- Ownership
- Privately Held (backing)
AirNexis Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AirNexis Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AirNexis Therapeutics in its N-PORT filings yet. We sweep new filings monthly.